Security
CytoDyn, Inc. Common Stock · CYDY
CYDYOTCCommon stockCurrentCIK 1175680Updated Oct 21, 2026
Name history
CYTODYN INC · through Apr 13, 2016REXRAY CORP · through Nov 12, 2003
CYDY price & chart
Loading TradingView…
OTC:CYDY on TradingView ↗About the company
CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
In the news
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab ↗
Recent filings
4 filing
DEFA14A filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
10-Q filing
EFFECT filing
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 18,497,000Source | 21,191,000Source | 10,270,000Source | 8,935,000Source | 24,877,000Source | 19,054,000Source | 13,483,000Source | 28,021,000Source | 13,973,000Source | 18,047,000Source | 11,136,000Source | 11,292,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,655,000Source | 16,400,000Source | 1,404,000Source | 4,982,000Source | 21,335,000Source | 16,359,000Source | 9,332,000Source | 24,921,000Source | 11,852,000Source | 11,903,000Source | 3,110,000Source | 2,541,000Source |
| Inventory, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Assets, CurrentUSD | 18,438,000Source | 20,984,000Source | 9,910,000Source | 8,839,000Source | 24,633,000Source | 18,983,000Source | 13,350,000Source | 27,738,000Source | 13,878,000Source | 17,878,000Source | 10,815,000Source | 10,805,000Source |
| Operating Lease, Right-of-Use AssetUSD | 33,000Source | 163,000Source | 298,000Source | 65,000Source | 196,000Source | 68,000Source | 98,000Source | 230,000Source | 73,000Source | 130,000Source | 264,000Source | 400,000Source |
| Other Assets, NoncurrentUSD | 59,000Source | 207,000Source | 360,000Source | 96,000Source | 244,000Source | 71,000Source | 133,000Source | 283,000Source | 95,000Source | 169,000Source | 321,000Source | 487,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 122,784,000Source | 114,170,000Source | 129,652,000Source | 128,683,000Source | 114,267,000Source | 117,127,000Source | 112,988,000Source | 113,231,000Source | 123,691,000Source | 114,089,000Source | 127,894,000Source | 120,793,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,358,000Source | 1,233,000Source | 990,000Source | 1,266,000Source | 1,224,000Source | 1,455,000Source | 1,257,000Source | 1,220,000Source | 1,374,000Source | 1,249,000Source | 1,059,000Source | 919,000Source |
| Additional Paid in CapitalUSD | 814,978,000Source | 787,618,000Source | 754,372,000Source | 794,919,000Source | 786,458,000Source | 850,893,000Source | 792,564,000Source | 785,874,000Source | 819,393,000Source | 790,495,000Source | 773,714,000Source | 731,270,000Source |
| Retained Earnings (Accumulated Deficit)USD | -920,623,000Source | -881,830,000Source | -874,744,000Source | -915,933,000Source | -877,072,000Source | -950,421,000Source | -893,326,000Source | -872,304,000Source | -930,485,000Source | -887,786,000Source | -891,531,000Source | -841,690,000Source |
| Stockholders' Equity Attributable to ParentUSD | -104,287,000Source | -92,979,000Source | -119,382,000Source | -119,748,000Source | -89,390,000Source | -98,073,000Source | -99,505,000Source | -85,210,000Source | -109,718,000Source | -96,042,000Source | -116,758,000Source | -109,501,000Source |
| Liabilities and EquityUSD | 18,497,000Source | 21,191,000Source | 10,270,000Source | 8,935,000Source | 24,877,000Source | 19,054,000Source | 13,483,000Source | 28,021,000Source | 13,973,000Source | 18,047,000Source | 11,136,000Source | 11,292,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 50,428,000Source | 70,565,000Source | 129,476,000Source | 85,112,000Source | 70,627,000Source | 49,700,000Source | 69,417,000Source | 69,555,000Source | 53,727,000Source | 70,518,000Source | 84,182,000Source | 119,796,000Source |
| Operating Lease, Liability, CurrentUSD | 34,000Source | 142,000Source | 142,000Source | 69,000Source | 141,000Source | 23,000Source | 105,000Source | 142,000Source | 23,000Source | 141,000Source | 142,000Source | 139,000Source |
| Accounts Payable, CurrentUSD | 13,478,000Source | 15,127,000Source | 62,078,000Source | 14,245,000Source | 14,244,000Source | 13,161,000Source | 14,175,000Source | 14,159,000Source | 13,155,000Source | 14,692,000Source | 29,561,000Source | 62,725,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 34,000Source | 176,000Source | — | 69,000Source | 47,000Source | — | 105,000Source | 53,000Source | 0Source | 141,000Source | 283,000Source |
| Other Liabilities, NoncurrentUSD | 43,571,000Source | 43,571,000Source | — | 43,571,000Source | 43,571,000Source | 43,571,000Source | 43,571,000Source | 43,571,000Source | 43,571,000Source | 43,571,000Source | 43,571,000Source | — |
| Additional Financial Items | ||||||||||||
| Dividends Payable, CurrentUSD | 9,375,000Source | 7,897,000Source | 6,418,000Source | 9,011,000Source | 7,532,000Source | 10,016,000Source | 8,642,000Source | 7,163,000Source | 9,647,000Source | 8,269,000Source | 6,791,000Source | 5,308,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | — | — | — | 5,417,000Source |
| Long-term DebtUSD | 40,535,000Source | 45,837,000Source | 44,249,000Source | 42,171,000Source | 46,084,000Source | 35,809,000Source | 43,777,000Source | 45,310,000Source | 38,340,000Source | 45,351,000Source | 45,020,000Source | 45,729,000Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 524,000Source | 179,000Source | 1,630,000Source | 1,612,000Source | 2,415,000Source | 4,275,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -7,726,000Source | -2,450,000Source | -17,252,000Source | -8,765,000Source | -10,982,000Source | -25,110,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 12,233,000Source | -121,000Source | 17,201,000Source | 10,854,000Source | 11,748,000Source | 29,927,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 4,507,000Source | -2,571,000Source | -51,000Source | 2,089,000Source | 766,000Source | 4,817,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 15,655,000Source | 16,400,000Source | 4,982,000Source | 21,335,000Source | 16,359,000Source | 9,332,000Source | 11,852,000Source | 11,903,000Source | 9,814,000Source | 9,048,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 0Source | 13,000Source | 22,000Source | 25,000Source | 45,000Source | 19,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | 572,000Source | 9,747,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | 407,000Source | 1,511,000Source | 2,195,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 100,000Source |
| DepreciationUSD | — | — | — | 5,000Source | — | 4,000Source | — | — | — | — | 29,000Source | — |
| Dividends Payable, CurrentUSD | — | — | 9,375,000Source | 7,897,000Source | 9,011,000Source | 7,532,000Source | 10,016,000Source | 8,642,000Source | 9,647,000Source | 8,269,000Source | 6,791,000Source | 5,308,000Source |
| Dividends PayableUSD | — | — | — | — | — | — | — | — | — | — | — | 5,417,000Source |
| Gain (Loss) on Sale of DerivativesUSD | — | — | — | — | — | — | — | — | 0Source | -852,000Source | -236,000Source | -8,750,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | -12,272,000Source | 0Source | — | — | -13,374,000Source | — |
| General and Administrative ExpenseUSD | — | — | 1,654,000Source | 1,516,000Source | 1,799,000Source | 2,298,000Source | 2,056,000Source | 1,713,000Source | 7,449,000Source | 7,260,000Source | 10,789,000Source | 17,136,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | — | — | 20,633,000Source |
| Investment Income, InterestUSD | — | — | 15,000Source | 173,000Source | 57,000Source | 142,000Source | 54,000Source | 94,000Source | 257,000Source | 565,000Source | — | — |
| LitigationSettlementLossUSD | — | — | — | — | 16,587,000Source | — | — | — | 15,430,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,690,000Source | -4,758,000Source | -22,607,000Source | -4,768,000Source | -19,936,000Source | -5,540,000Source | -42,699,000Source | 3,745,000Source | -49,841,000Source | -79,824,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -5,054,000Source | -5,123,000Source | -22,976,000Source | -5,137,000Source | -20,310,000Source | -5,913,000Source | -44,180,000Source | 2,261,000Source | -51,324,000Source | -86,736,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 900,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 21,000Source | 149,000Source | 106,000Source | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | — | — | — | — | — | -6,000Source |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Operating Income (Loss)USD | — | — | -6,303,000Source | -4,003,000Source | -21,688,000Source | -3,707,000Source | -6,577,000Source | -4,945,000Source | -38,575,000Source | 9,661,000Source | -18,058,000Source | -40,576,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -4,690,000Source | -4,758,000Source | -22,607,000Source | -4,768,000Source | -19,936,000Source | -5,540,000Source | -42,699,000Source | 3,745,000Source | -49,841,000Source | -79,824,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,690,000Source | -4,758,000Source | -22,607,000Source | -4,768,000Source | -19,936,000Source | -5,540,000Source | -42,699,000Source | 3,745,000Source | -49,841,000Source | -79,824,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | 0Source | -0.02Source | 0Source | -0.01Source | 0Source | -0.03Source | 0Source | -0.05Source | -0.1Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0Source | -0.02Source | 0Source | -0.01Source | 0Source | -0.03Source | 0Source | -0.05Source | -0.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,275,184,000Source | 1,228,259,000Source | 1,261,016,000Source | 1,221,405,000Source | 1,382,223,000Source | 1,252,551,000Source | 1,289,302,000Source | 1,205,755,000Source | 969,509,000Source | 836,528,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,275,184,000Source | 1,228,259,000Source | 1,261,016,000Source | 1,221,405,000Source | 1,382,223,000Source | 1,252,551,000Source | 1,289,302,000Source | 1,242,922,000Source | 969,509,000Source | 836,528,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | — | 100,000Source |
| Costs and ExpensesUSD | — | — | 6,303,000Source | 4,003,000Source | 21,688,000Source | 3,707,000Source | 6,577,000Source | 4,945,000Source | 38,575,000Source | -9,661,000Source | 18,058,000Source | 40,576,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 19,000Source | 4,000Source | 17,000Source | 18,000Source | 29,000Source | 175,000Source |
| General and Administrative ExpenseUSD | — | — | 1,654,000Source | 1,516,000Source | 1,799,000Source | 2,298,000Source | 2,056,000Source | 1,713,000Source | 7,449,000Source | 7,260,000Source | 10,789,000Source | 17,136,000Source |
| Investment Income, InterestUSD | — | — | 15,000Source | 173,000Source | 57,000Source | 142,000Source | 54,000Source | 94,000Source | 257,000Source | 565,000Source | — | — |
| LitigationSettlementLossUSD | — | — | — | — | 16,587,000Source | — | — | — | 15,430,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -5,054,000Source | -5,123,000Source | -22,976,000Source | -5,137,000Source | -20,310,000Source | -5,913,000Source | -44,180,000Source | 2,261,000Source | -51,324,000Source | -86,736,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | 364,000Source | 365,000Source | 369,000Source | 369,000Source | -374,000Source | -373,000Source | 1,481,000Source | 1,483,000Source | 1,483,000Source | 1,495,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 7,240,000Source | 2,632,000Source |
| Cost, Depreciation and Amortization | — | — | — | — | — | — | — | —Source | — | — | — | — |
Offerings
Registration 333-282000
Registration 333-295250
Registration 333-299150
Filing attachments
ck0001175680-ex99_1.htm · 8-K · 2026-10-19
Exhibit 99.1 CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, October 19, 2026 -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer …
Read attachment ↗ck0001175680-ex99_2.htm · 8-K · 2026-10-19
CYTODYN INVESTOR UPDATE WEBINAR THE WEBINAR WILL START SOON Participants Jacob Lalezari M.D. Chief Executive Officer of CytoDyn Robert E. Hoffman Chief Financial Officer of CytoDyn Medical Director of GI Oncology, City of Hope Orange County, Irvine, California Pashtoon M. Kasi M.D., M.S. Sr. Director of BioPharma Business Development, Oncology & RWD Solutions, Natera Reny Aniline The Next Generation of Monoclonal Antibody Therapy CYTODYN. COM / OTCMKTS: CYDY FORWARD LOOKING STATEMENT This pres…
Read attachment ↗ck0001175680-ex4_1.htm · 10-K · 2026-08-31
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S CAPITAL STOCK General CytoDyn, Inc. (the “Company” or “we”) is authorized to issue up to 2,255,000,000 shares of capital stock, including 2,250,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. As of August 28, 2026, we had 1,466,269,460 shares of common stock, 19,000 shares of Series B Convertible Preferred Stock (“Series B Preferred Stock”), 6,195 shares of Series C Con…
Read attachment ↗ck0001175680-ex99_1.htm · 8-K · 2026-04-30
EX-99.1 2 ck0001175680-ex99_1.htm EX-99.1 Leronlimab - A Novel Therapeutic in CCR5+ Immuno-Oncology CYTODYN. COM / OTCMKTS: CYDY FORWARD LOOKING STATEMENT This presentation contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans…
Read attachment ↗cydy-20251103xex99d1.htm · 8-K · 2025-11-03
EX-99.1 3 cydy-20251103xex99d1.htm EX-99.1 Exhibit 99.1 CytoDyn Secures $30 Million Commitment from Yorkville Advisors VANCOUVER, Washington, November 3, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorecta…
Read attachment ↗cydy-20250502xex99d1.htm · 8-K · 2025-05-06
EX-99.1 3 cydy-20250502xex99d1.htm EX-99.1 Exhibit 99.1 CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer VANCOUVER, Washington, May 6, 2025 - CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E. Hoffman has been appointed as Chief Financial Officer, effective May 15, 2025. He will take over the CFO position…
Read attachment ↗